Creative Planning’s Aclaris Therapeutics ACRS Stock Holding History

Creative Planning’s Portfolio ACRS Stock Details ACRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.09M	Buy	206,647 +54,559	+36%	+$243K	﹤0.01%	2568
2026 Q1	$570K	Buy	152,088 +100,917	+197%	+$341K	﹤0.01%	2927
2025 Q4	$154K	Buy	+51,171	New	+$129K	﹤0.01%	3630
2021 Q2	–	Sell	-17,740	Closed	-$447K	–	2058
2021 Q1	$447K	Sell	17,740 -2,760	-13%	-$54K	﹤0.01%	1513
2020 Q4	$133K	Sell	20,500 -9,500	-32%	-$40.1K	﹤0.01%	1982
2020 Q3	$77K	Sell	30,000 -76	-0.3%	-$170	﹤0.01%	1861
2020 Q2	$49K	Hold	30,076	–	–	﹤0.01%	1767
2020 Q1	$31K	Hold	30,076	–	–	﹤0.01%	1685
2019 Q4	$57K	Hold	30,076	–	–	﹤0.01%	1810
2019 Q3	$32K	Buy	+30,076	New	+$42.7K	﹤0.01%	1826

Other funds holding ACRS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return

Creative Planning's ACRS Position: Q2 2026 in Review

Creative Planning increased its Aclaris Therapeutics (ACRS) stake by 36% in Q2 2026, buying an estimated $243K and bringing the position to 206,647 shares worth $1.09M. The position accounts for ﹤0.01% of the portfolio, ranked #2568.

Creative Planning first reported a position in ACRS in Q3 2019 and has held it in 10 quarters since. 149 funds tracked by Wall St. Rank hold ACRS as of Q2 2026.

Creative Planning held 206,647 shares of Aclaris Therapeutics worth $1.09M as of Q2 2026.
Creative Planning bought 54,559 Aclaris Therapeutics shares in Q2 2026, an estimated $243K.
Aclaris Therapeutics made up ﹤0.01% of Creative Planning's portfolio in Q2 2026, its #2568 holding.
Creative Planning first reported a position in Aclaris Therapeutics in Q3 2019 and has held it in 10 quarters since.
149 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2026.

Based on Creative Planning's 13F filing for Q2 2026, filed 13 Aug 2026.